Design, facile synthesis and characterization of dichloro substituted chalcones and dihydropyrazole derivatives for their antifungal, antitubercular and antiproliferative activities

Article abstract of DOI:10.3390/molecules25143188

Infectious diseases caused by fungi and mycobacteria pose an important problem for humankind. Similarly, cancer is one of the leading causes of death globally. Therefore, there is an urgent need for the development of novel agents to combat the deadly pro

Full text of DOI:10.3390/molecules25143188

molecules
Article
Design, Facile Synthesis and Characterization of
Dichloro Substituted Chalcones and Dihydropyrazole
Derivatives for Their Antifungal, Antitubercular and
Antiproliferative Activities
Afzal B. Shaik 1,
* ,
, Richie R. Bhandare 2,*, Srinath Nissankararao 3 , Zehra Edis 2
N. Ravikiran Tangirala 4, Shaik Shahanaaz 5 and M. Mukhlesur Rahman 6,
*
1
Department of Pharmaceutical Chemistry, Vignan Pharmacy College, Jawaharlal Nehru Technological
University, Vadlamudi 522 213, India
Department of Pharmaceutical Sciences, College of Pharmacy & Health Sciences, Ajman University,
Ajman PO Box 346, UAE; z.edis@ajman.ac.ae
Independent Researcher, Montvale, NJ 07645, USA; srinath.n2k@gmail.com
Department of Pharmaceutical Chemistry, Narasaraopeta Institute of Pharmaceutical Sciences, Jawaharlal
Nehru Technological University, Narsaraopet 522 601, India; ravikirannaga58@gmail.com
Department of Pharmaceutical Chemistry, Victoria College of Pharmacy, Nallapadu, Guntur District 522 001,
India; shahanaazchemistry@gmail.com
2
3
4
5
6
Medicines Research Group, School of Health, Sports and Bioscience, University of East London,
Stratford Campus, Water Lane, London E15 4LZ, UK
*
Correspondence: bashafoye@gmail.com (A.B.S.); r.bhandareh@ajman.ac.ae (R.R.B.);
m.rahman@uel.ac.uk (M.M.R.); Tel.: +91-9966-014-374 (A.B.S.); +971-565646655 (R.R.B.);
+44-7578022845 (M.M.R.)
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
Academic Editors: Diego Muñoz-Torrero and Beatriz De Pascual-Teresa
Received: 9 June 2020; Accepted: 11 July 2020; Published: 13 July 2020
ꢀꢁꢂꢃꢄꢅꢆ
Abstract: Infectious diseases caused by fungi and mycobacteria pose an important problem for
humankind. Similarly, cancer is one of the leading causes of death globally. Therefore, there is
an urgent need for the development of novel agents to combat the deadly problems of cancer,
tuberculosis, and also fungal infections. Hence, in the present study, we designed, synthesized, and
characterized 30 compounds including 15 chalcones (2–16) and 15 dihydropyrazoles (17–31) containing
dichlorophenyl moiety and also screened these compounds for their antifungal, antitubercular, and
antiproliferative activities. Among these compounds, the dihydropyrazoles showed excellent
antifungal and antitubercular activities whereas the chalcones exhibited promising antiproliferative
activity. Among the dihydropyrazoles, compound 31 containing 2-thienyl moiety showed promising
antifungal activity (MIC 5.35
and 4-trifluoromethyl scaffolds revealed significant antitubercular activity with the MICs of 3.96
and 3.67 M, respectively. Compound 16 containing 2-thienyl moiety in the chalcone series showed
the highest anti-proliferative activity with an IC50 value of 17 M. The most active compounds
µM), whereas compounds 22 and 24 containing 2,4-difluorophenyl
µ
±
1 µ
identified through this study could be considered as starting points in the development of drugs with
potential antifungal, antitubercular, and antiproliferative activities.
Keywords: chalcone; dihydropyrazole; antifungal; antitubercular; antiproliferative activity
1. Introduction
Chalcones are a class of natural products characterized by the presence of two aromatic rings
connected through
α,β-unsaturated ketone moiety. Hence, these are a type of 1,3-diphenyl-2-propene-
1-ones which serve as precursors for the synthesis of different classes of flavonoids and isoflavonoids—a
Molecules 2020, 25, 3188; doi:10.3390/molecules25143188
www.mdpi.com/journal/molecules

Molecules 2020, 25, 3188
2 of 16
class of biologically important of natural products. The
α
,
β-unsaturated ketone moiety is highly reactive,
making the chalcones valuable starting materials for the synthesis of a range of heterocyclic compounds
of ring size of 5, 6, or 7 with nitrogen, oxygen, and sulfur as hetero atoms [ ]. Chalcone derivatives,
which are excellent starting points in drug design [ ], are well-known for varied biological activities
such as antimicrobial, anticancer, antimalarial, antioxidant, anti-tubercular, anti-inflammatory, and
anti-tumor activities [ 15]. Dihydropyrazole is an interesting heterocyclic compound, which can be
1
2–7
8–
synthesized from chalcones. Compounds containing dihydropyrazole skeletons have been reported to
possess varied activities such as antibacterial, antifungal, anticancer, analgesic, and anti-inflammatory
activities [16
chalcones and dihydropyrazoles with significant antioxidant, antibacterial, antifungal, antitubercular,
cytotoxic, and anticancer activities [21 28]. Previous reports published in the literature suggest that the
–20]. We have previously reported various phenyl-substituted and heterocycle-based
–
presence of chalcones (Figure 1 I,II) and dihydropyrazoles (Figure 1 III,IV) substituted with chlorine
and other substituents such as heterocycle-based chalcones and dihydropyrazole derivatives are
essential structural features for biological activities including antifungal, antibacterial, anticancer, and
antioxidant activities [2,5,15,29–33]. For example, chlorinated chalcones I and II showed significant
antibacterial activities against both Gram-positive (Staphylococcus aureus and Bacillus subtilis) and
Gram-negative bacteria (Pseudomonas aeruginosa and E. coli) and antifungal activity against Candida
albicans, Aspergillus niger and Penicillium chrysogenum [4]. The understanding of chlorine’s affect on
biological activity was further facilitated by data generated through computational analysis [34] which
suggested that the presence of chlorine atoms along with another electrophilic substituents on the
aromatic ring retains/enhances biological activities such as antimicrobial properties [34].
Figure 1. Structures of chlorinated and heteroaryl-based chalcones and dihydropyrazoles with potential
biological activities.
The presence of chlorine as a substituent in many drugs appears to be responsible for bioactivity.
Fang et al. [35] reported that a total of 163 compounds out of the 233 drugs approved for clinical uses
contain chlorine in their structures. Among the 163 compounds, nearly 73% of them possess one
chlorine atom whilst 23%, 2.6%, 1.4%, and 2.5% of such compounds were found to have two, three, four,
and six chlorine atoms in their molecular structures, respectively [35]. The current market for chlorine
containing drugs is worth approximately USD 168.5 billion, of which anti-infectives and cytostatics
account for USD 9.5 and 12.7 billion, respectively [36]. The presence of one or more chlorine atoms is
the prominent feature in antibiotic, antifungal, antileprotic, antiviral, and anticancer agents (Figure 2).

Molecules 2020, 25, 3188
3 of 16
Figure 2. Structures of selected drugs containing one or more chlorine atoms.
The term “mycos”, as in the term “mycology” (the study of fungi), means waxy, which
indicates that the cell walls of fungal and mycobacterial microorganisms are hydrophobic in nature.
Therefore, lipophilicity is an important concern for designing molecules to act as better antifungal and
antitubercular agents. It was observed that the incorporation of a chlorine substituent in one or the other
specific locations of the pharmacologically active molecules improved their inherent bioactivity [37].
The presence of the chlorine atom as a substituent improves the lipophilicity of the molecule and in
turn favors the greater partitioning of the chlorinated compounds into the lipophilic component of the
cell membranes or the lipophilic domains of the protein molecule. This leads to a higher concentration
of the molecule at the site of action and may result in improved bioactivity. The chlorine atom present
in the alkyl chain is highly reactive and readily undergoes nucleophilic aliphatic substitution reaction
in the body [38]. The chlorine present as a substituent on an aromatic or heteroaromatic ring or olefinic
fragment is non-reactive, hence it will be carried by the molecule to the site of action where it may help
in the efficient binding of the drug molecule with the target through the electronic and/or steric effects of
chlorine [38]. In addition to its lipophilicity and membrane penetrability, another important feature of
the presence of the chlorine atom in molecules is its ability to form halogen bonding. The participation
of halogen bonding is evident in ligand–receptor interactions due to its unique ability to act as both
Lewis acid and Lewis base [39,40]. Hence, the presence of the chlorine atoms in the chemical structure
will enhance the required lipophilicity, aid in the penetration of the molecule, facilitate halogen bonding
and in turn help to increase bioactivity. Halogen bonding plays the same important role in polyiodides
related to antimicrobial activities and lipophilicity [41–43]. As a part of our ongoing research as well as
based on the information published in the literature and our previously reported work, here we report
the design and facile synthesis of dichloro-substituted chalcones and dihydropyrazoles (Figure 3) for
their antifungal, anti-tubercular and antiproliferative activities.

Molecules 2020, 25, 3188
4 of 16
Figure 3. Newly designed chlorine containing chalcones and dihydropyrazole derivatives.
2. Results and Discussion
2.1. Chemistry
Chalcones (
2
–
16) were prepared by a Claisen–Schmidt condensation reaction in the presence of
) was condensed with
alcoholic potassium hydroxide as a catalyst. The 3,4-dichloroacetophenone (
1
substituted benzaldehyde by stirring under basic conditions at room temperature for 24 h followed by
transferring the mixture to a beaker containing crushed ice. The crude precipitate was recrystallized
using ethanol to afford chalcones 2–16 (Scheme 1). The target dihydropyrazoles 17–31 were obtained
by refluxing the synthesized chalcones with phenyl hydrazine for 6–8 h in glacial acetic acid and
purified using silica gel column chromatography (Scheme 1). The synthesized compounds
2 [44],
3 [45], 4–6 [44], 10 [46], and 13 [47] were characterized by various spectroscopic methods including
FTIR, 1H-NMR, 13C-NMR, and MS. (Spectral data are provided in the supplementary material).
Scheme 1. Protocol for the synthesis of dichlorophenyl rings containing chalcones and dihydropyrazole
derivatives; RT: room temperature.
All the synthesized chalcones exhibited characteristic absorption bands in the FTIR spectra (cm−1
in the ranges 1640–1660 (C=O), 1570–1605 (C=C quadrant of Ar), and 1500–1550 (HC=CH), and at
)

Molecules 2020, 25, 3188
5 of 16
other regions of the spectrum depending upon the specific substituents present in each compound.
The 1H-NMR spectrum (400 MHz, CDCl3) of the chalcones revealed the characteristic ethylenic protons
of the α,β-unsaturated ketone system between δ 6.85 and 8.10 ppm as two doublets. A higher chemical
shift value at 8.10 ppm was observed for the protons beta to the carbonyl group. The spectra also
showed the peaks accounting for the aromatic protons and for the different substituent protons between
the corresponding regions of the spectrum.
Compound 17 was analyzed for C22H18Cl2N2, melting point (m.p.) 168 ◦C, well supported by
its molecular ion [M]+ that appeared at m/z 381.30 in its mass spectrum. The spectrum also showed
an isotope satellite signal (37Cl) with one-third intensity at m/z 383.30. The FTIR spectrum (KBr disc)
showed characteristic intense absorption bands at 1592 (C=N), 1120 (C-N), 1586 (C=C quadrant of Ar),
and 830 (C-Cl) cm−1. The 1H-NMR spectrum (400 MHz, CDCl3) showed the characteristic HA, HB,
and HX protons at
JAX = 7.50 Hz and JBX = 9.35 Hz respectively. The spectrum also accounted for all 12 aromatic protons
that appeared in the range
6.75–7.91. The 13C-NMR spectrum (100 MHz, CDCl3) showed all the
carbon resonances characteristic of the above compound at 152.50 (C-3), 66.54 (C-5), 45.50 (C-4),
133.95 (C-20 and C-200), 143.51 (C-30 and C-300), 134.88 (C-40 and C-400), and in the range
112.12–145.96
δ 3.28, 3.72, and 5.45, respectively, as doublet of doublets (dd) with JAB = 16.95 Hz,
δ
δ
δ
for all the carbons of the phenyl ring. Based on the above spectral data, the structure of compound 17
was confirmed as 3-(3,4-dichlorophenyl)-1-phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazole.
2.2. Biological Studies
All the compounds synthesized through this study were evaluated for their antifungal,
antitubercular, and antiproliferative activities employing standard protocols. The antiproliferative
and cytotoxic studies on the synthesized compounds were carried out at Chemiloids Life Sciences
Pvt Limited, Vijayawada, Andhra Pradesh, India. The compounds were sorted into three different
categories based on their structural features. For instance, compounds
monosubstituted chalcones and dihydropyrazoles, whereas compounds
disubstituted chalcones and dihydropyrazoles, and compounds 10
2
–
6
,
9
7, 8,
,
17
–
21, and 24 represented
22, and 23 represented
16 and 25 31 represented the
–
–
bioisosteric substitution of a phenyl ring.
2.2.1. Antifungal Activities
In the monosubstituted chalcone series (Table 1)
substituted by either CH3 ( ), F (3, 4), or Cl ( ) groups. The chalcone (
showed the lowest antifungal activity with an MIC of 109.9 M. Replacing methyl (CH3) substituent (
with fluorine (F) ( ) or chlorine (Cl) ( ) resulted in two- and fourfold improvement in activity against
2–
6
and
9, the para and ortho position were
2
5,
6
2) with methyl substituent
µ
2)
3
5
Aspergillus niger, respectively, but twofold improvement against Candida tropicalis in the case of both
compounds. Changing the position of F from para to ortho (3 vs 4) resulted in twofold improvement
in activity against Aspergillus niger but no change was observed against Candida tropicalis. At the
ortho position, when F was substituted with Cl (
Aspergillus niger and Candida tropicalis. When the CH3 group at the para position (
a highly electron-withdrawing group such as CF3 ( ), it resulted in twofold and 1.6 fold improvement
in activity of 11.58 M against Aspergillus niger and Candida tropicalis, in comparison to the reference
drug fluconazole (MIC 26.11 and 19.58 M against Aspergillus niger and Candida tropicalis), which
suggests that a highly electron-withdrawing group is suitable at this position.
In the disubstituted chalcones and , substituting another F or Cl on the para position of
compounds and resulted in no change in activity. In the bioisosteric chalcone series, substituting
a phenyl ring with methylene dioxyphenyl (10) resulted in MIC of 23 M against Aspergillus niger
M). Among the six-membered heterocycles 11
M) against Candida tropicalis. It also appeared
4
vs.
6), no change in activity was observed against
2) was replaced with
9
µ
µ
7
8
4
6
µ
but poor activity against Candida tropicalis (MIC 180
to 13, compound 12 demonstrated better MIC (14.43
µ
µ
that nitrogen at position 3 on the pyridine ring (12) showed better activity against positions 2 (11
)
and 4 (13). Among the five-membered bioisostere-based compounds, substituting chalcones 14 to 16

Molecules 2020, 25, 3188
6 of 16
with the 2-thienyl group (16) exhibited the best antifungal activity of 14.12
µM. Other bioisosteres,
such as 2-furfuryl (14) and 2-pyrrolyl (15), showed low and modest activity (MICs 234.97, 117.48, and
60.37 M). Compound 16 with the 2-thienyl group was found to be similar in activity (MIC 14.12 M)
to compound (MIC 11.58 M) in comparison with other mono- and disubstituted phenyls and
µ
µ
9
µ
six-membered heterocyclic rings containing chalcones. The most potent among the heterocycle-based
chalcone series was compound 16, with 1.84- and 1.35-fold better activity against Aspergillus niger and
Candida tropicalis in comparison to fluconazole.
The dihydropyrazole series fared better than the chalcones. The overall antifungal activity of
the dihydropyrazole series ranged from 5.35–41.96
24, antifungal activity ranged from 9.18–41.96 M against Aspergillus niger and Candida tropicalis.
Para substitution with CH3 (17) gave the lowest activity among the monosubstituted series with an
MIC of 41.96 M. Replacing CH3 with the highly electronegative substituent CF3 (24) caused 4.6-fold
µM. In the monosubstituted series 17–21 and
µ
µ
improvement in activity against both species suggesting that an electron-withdrawing group at the
para position is favored for activity. When the CH3 group was replaced with either F (18) or Cl (20),
antifungal activity was improved twofold to 28.76
ortho position with F (19) or Cl (21) showed identical MICs with the para position having F (18) and
Cl (21) (20.76 and 19.91 g/mL for Aspergillus niger and 41.53 and 39.82 M for Candida tropicalis,
µM against Aspergillus niger. Substitution at the
µ
µ
respectively). In the monosubstituted chalcone series, compound 24 fared 2.84- and twofold better in
activity over fluconazole against Aspergillus niger and Candida tropicalis.
In the disubstituted compounds 22 and 23, F and Cl substitution at ortho and para did not show
any improvement in antifungal activity in comparison to compounds 18
–
21. Compound 22 only
M) against Candida tropicalis in comparison
31), the activity ranged from 5.35–44.91 M.
M against Aspergillus niger and
Candida tropicalis, similar to standard fluconazole. Substitution on the pyridine ring at the 20, 30, or 40
position (26 28) did not alter antifungal activity (MIC 21.72 M). In the five-membered heterocycles
29 31), the best activity was observed for compound 31 (MIC 5.35 M) and it was found to be 4.9 and
3.7-fold better in activity over standard fluconazole against Aspergillus niger and Candida tropicalis.
showed twofold improvement in activity (MIC 19.83
µ
to compounds 18 and 19. Among the bioisosteres (25
–
µ
The bioisostere 3,4-methylenedioxyphenyl (25) had an MIC of 19.45
µ
–
µ
(
–
µ
In comparison to chalcone
9
, the monosubstituted series containing dihydropyrazole 24 showed
similar MICs of 11.58 and 9.18
µM against both fungi. However, in the five-membered heterocycle,
dihydropyrazoles fared better than chalcones, showing 2.6-fold improvement in MIC (31, 5.35 µM vs 16,
14.12 µM) indicating that antifungal activity proceeded better in dihydropyrazoles than in chalcones.
Table 1. Antifungal activities (MIC in µM) of chalcones (2–16) and dihydropyrazoles (17–31).
Compound
A. niger
C. tropicalis
Compound
A. niger
C. tropicalis
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
109.9
54.21
27.10
25.67
25.67
25.54
23.11
109.9
54.21
54.21
51.34
51.34
51.09
46.23
11.58
180.62
28.87
14.43
112.8
117.48
60.37
14.12
19.58
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
41.96
20.76
20.76
19.91
19.91
19.83
18.34
9.18
19.45
21.72
21.72
21.72
11.19
44.91
5.35
41.96
41.53
41.53
39.82
39.82
19.83
36.68
9.18
19.45
21.72
21.72
21.72
11.19
44.91
5.35
23.11
28.87
28.87
57.75
234.97
60.37
14.12
26.11
Fluconazole
Fluconazole
26.11
19.58

Molecules 2020, 25, 3188
7 of 16
2.2.2. Antitubercular Activity
In the monosubstituted chalcone series (Table 2), substitution with the CH3 (
2) group at the para
position of the phenyl ring resulted in the lowest activity of 343.44
or Cl, it showed fourfold improvement in activity (MIC 84.70 M) indicating that the electronegative
halogen substituent was favorable over the electron-releasing group. Hence, when CH3 was substituted
with CF3, the activity was improved by approximately 40-fold for (MIC 9.03 M) vs. compound
M). Substitution with other electronegative functional groups, such as fluorine in
and at para and ortho positions, showed similar activity with an MIC of 84.70 M.
containing chlorine at the ortho position (MIC 20.05 M) showed a fourfold
increase in activity compared with which had chlorine at the para position (MIC 80.23 M). Overall,
showed 2.8-fold better activity than the standard
µM. When CH3 was replaced with F
µ
9
µ
2
(MIC 343.44
compounds
µ
3
4
µ
However, compound
6
µ
5
µ
in the monosubstituted series of chalcones,
9
pyrazinamide (MIC 9.03 vs. 25.34 µM).
Table 2. Antitubercular activity (MIC in µM) of chalcones (2–16) and dihydropyrazoles (17–31).
Compound
M. tuberculosis H37Rv
Compound
M. tuberculosis H37Rv
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
343.44
84.70
84.70
80.23
20.05
9.96
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
262.26
32.44
32.44
31.11
15.55
3.96
18.06
9.03
7.15
3.67
72.24
45.12
22.56
45.12
46.99
47.16
22.07
25.34
60.78
67.88
67.88
67.88
17.49
70.17
8.35
Pyrazinamide
25.34
Among the disubstituted chalcones, the incorporation of F (
para positions resulted in activity nearly equal to that of compound
with Cl (
22.07 to 72.24
an MIC of 22.56
7
; MIC 9.96
µ
M) at both ortho and
9
(MIC 9.03
µM)). Replacing F (7)
8
) caused a nearly twofold drop in activity. Among the bioisosteres, the MIC ranged from
M. Among the six-membered heterocycles, substitution with 3-pyridyl (12) resulted in
M, an activity greater than pyrazinamide whereas compounds 11 and 13 containing 2-
µ
µ
and 4-pyridinyl scaffolds showed half the potency of that shown by compound 12 and pyrazinamide,
indicating the significance of the point of attachment on the pyridine ring. Among the five-membered
heterocycles, 2-thienyl (16) gave the best activity at 22.07 µM and was found to be comparable with
pyrazinamide. Substitution of the 2-thienyl ring with 2-furfuryl (14) or 2-pyrrolyl (15) resulted in a
twofold drop in activity.
The dihydropyrazoles in most of the cases showed activity at lower MIC values than the
corresponding chalcones. This designates that the dihydropyrazole derivatives are more promising
antitubercular agents than the compounds belonging to the chalcone series. In the monosubstituted
series, compound 17 containing the CH3 group was the least potent in the dihydropyrazole series
with MIC 262.26
µM whereas the other compounds 18
–21 containing fluorine and chlorine atoms
showed activity ranging from 15.55 to 32.44
µM. Compound 21 containing Cl at ortho position showed
1.6 times more activity than pyrazinamide whereas compounds 18 and 19 containing F at ortho and
para positions as well as 20 with Cl at para position showed 1.2-fold less activity than pyrazinamide.
Compound 24 containing CF3 showed top-class activity with an MIC of 3.67
µM, and this was the
most potent among the thirty tested compounds having sevenfold greater activity than pyrazinamide.

Molecules 2020, 25, 3188
8 of 16
However, in the case of the disubstituted compounds 22 and 23, when the ortho and para positions
were substituted with F as in 22 (MIC, 3.96 M) the activity improved eightfold. Similarly, the activity
of compound 23 (MIC, 7.15 M) bearing Cl atoms at ortho and para positions showed 4- and 2-fold
µ
µ
improvement in activity compared to compounds 20 and 21, respectively.
Among the bioisosteres, there was a drop in the activity of the six-membered heterocycles 26–28
containing pyridine attachments (20, 30, and 40, MIC = 67.88
µM) compared to the corresponding
chalcones 11
–13. Similarly, 30, bearing a five-membered nitrogen-containing pyrrole nucleus, had
a 1.5-fold reduction in activity compared with 15. However, the other two compounds 29 and 31
containing five-membered heterocycles 20-furyl and 20-thienyl moieties showed 2.6-fold more activity
than the chalcones 14 and 16. Overall from the SAR study, we can infer that dihydropyrazole-based
compounds showed improvement in antitubercular activity over chalcones, and that compounds
bearing halogen atoms such as fluorine and chlorine especially are crucial for activity in both chalcones
and dihydropyrazole derivatives.
2.2.3. Antiproliferative and Cytotoxicity Activity
In the monosubstituted chalcone series
disubstituted compounds , the IC50 observed ranged from 31
than by a factor of eight. In bioisosteric substitution, the activity ranged from 17
2
–
6
and
9
activity ranged from 141
±
2 to 432
±
2
µ
M. In the
being better
M.
7–8
±
2
µM to 254
±
2
µ
M,
1 to 353
7
8
±
±
2 µ
The best activity in the chalcone series was observed for 2-thienyl bioisostere (16) with an IC50 of
17±1 µM, but this was found to be less than the reference standard methotrexate (11 ± 1 µM).
Among the dihydropyrazoles 17
–
31, activity ranged from 32
±
±
1 to 351
2 to 351
±
2
µM. Among the
monosubstituted series 17
–
21 and 24, the activity ranged from 134
±
2 µM. Substituting
additional F or Cl (compounds 22 and 23) did not bring about any improvement in activity over
the monosubstituted compounds 19 and 21. Among the bioisosteres 25
32 2 to 271 M. The best activity was observed for 2-thienyl bioisostere (31) with ab IC50
of 32 M. This activity was found to be three times lower than the activity of the reference
standard methotrexate (11 M). Overall, the chalcones fared better than the dihydropyrazoles in
antiproliferative activity (Table 3). The cytotoxicity activity of chalcones 16 was more than 50 g/mL
whereas that of dihydropyrazoles and methotrexate (positive control) was greater than 75 g/mL on
the normal cell lines (L02) (Table 4). Hence, these compounds were non-toxic against normal human
–31, activity ranged from
±
±
2 µ
±
1 µ
±
1 µ
2
–
µ
µ
cells. A summary of the antifungal, antitubercular, and antiproliferative activities of chalcones (2–16)
and dihydropyrazoles (17–31) is depicted in Figure 4.
Table 3. Antiproliferative activity (IC50 in µM) of chalcones (2–16) and dihydropyrazoles (17–31).
Compound
DU-145
Compound
DU-145
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
432 ± 2
176 ± 2
393 ± 2
147 ± 2
141 ± 2
31 ± 2
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
11 ± 1
351 ± 2
119 ± 2
327 ± 2
149 ± 2
134 ± 2
262 ± 2
206 ± 2
257 ± 2
131 ± 2
271 ± 2
211 ± 2
173 ± 2
162 ± 2
84 ± 2
254 ± 2
292 ± 1
138 ± 2
353 ± 2
256 ± 2
209 ± 2
206 ± 2
94 ± 2
17 ± 1
32 ± 1
Methotrexate
Data are presented as mean
±
SD (n = 3). All the compounds and the standard were dissolved in dimethyl sulfoxide
(DMSO), diluted with culture medium containing 0.1% DMSO. The control cells were treated with culture medium
containing 0.1% DMSO.

Molecules 2020, 25, 3188
9 of 16
Table 4. Cytotoxic activity (IC50 in µg/mL) of chalcones (2–16) and dihydropyrazoles (17–31).
Compound
L02
Compound
L02
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
>75
>75
>75
>75
>75
>75
>75
>75
>75
>75
>75
>75
>75
>75
>75
>75
Methotrexate
Figure 4. Summary of the antifungal, antitubercular, and antiproliferative activities of chalcones (
and dihydropyrazoles (17–31).
2–16)

Molecules 2020, 25, 3188
10 of 16
3. Materials and Methods
3.1. Chemicals and Instruments
The chemicals, solvents, and reagents were purchased from S D Fine-Chem and Sigma Aldrich and
were used without further purification. Thin layer chromatography (TLC) was carried out on pre-coated
silica gel 60 F254 plates to monitor the reactions as well as to check the purity of the final products.
The spots were visualized by UV lamp (254 nm). The chalcones were purified by recrystallization,
whereas the dihydropyrazoles were purified by column chromatography employing silica gel (200 to
300 mesh) as the stationary phase and hexane-ethyl acetate as the mobile phase. Melting points were
determined using Boetius melting point apparatus in open capillary tubes and were uncorrected.
FTIR spectra were scanned using KBr discs on a Bruker Vertex 80v spectrometer whereas the 1H and
13C-NMR spectra were recorded on a Bruker AMX 400 MHz NMR spectrophotometer by dissolving
the compounds in CDCl3 with TMS as an internal standard. The 1H-NMR and 13C-NMR spectra were
recorded at operating frequencies of 400 and 100 MHz respectively and the chemical shift values are
given in parts per million (ppm) relative to TMS. Mass spectra (MS) were obtained on Agilent 6100
QQQ ESI mass spectrophotometer by the electron spray ionization technique.
3.2. Synthesis
3.2.1. General Procedure for the Synthesis of Chalcones (17–31)
A mixture of 3,4-dichloroacetophenone (1) (1 mmol) and the appropriate aryl or heteroaryl
aldehyde (1 mmol) was stirred in ethanol (7.5 mL) and an alcoholic solution of KOH (50%, 7.5 mL) was
added dropwise to it. The mixture was stirred for a period of 24 h, and it was then transferred into
crushed ice. Later, the precipitate formed was filtered under vacuum and the product was washed
thoroughly with water to remove the water-soluble impurities and dried. The dried precipitate was
further recrystallized from ethanol to obtain the crystals of chalcone derivatives (2–16).
(E)-1-(3,4-dichlorophenyl)-3-(2,4-difluorophenyl)prop-2-en-1-one (7
): Yield 83%; m.p. 265 ◦C; FTIR (KBr,
cm−1): 1656 (C=O), 1581 (C=C of Ar), 1512 (CH=CH), 829 (C-Cl), 926 (C-F); 1H-NMR (400 MHz, CDCl3,
ppm): 7.28 (1H, d, J = 17 Hz, -CO-CH=), 7.75 (1H, d, J = 17 Hz, =CH-Ar), 7.33–8.05 (6H, Ar-H).
(E)-1-(3,4-dichlorophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one (
8
): Yield 91%; m.p. 299 ◦C; FTIR (KBr,
1
cm−1): 1659 (C=O), 1582 (C=C of Ar), 1509 (CH=CH), 826 (C-Cl), 822 (C-Cl); H-NMR (400 MHz,
CDCl3, ppm): 7.31 (1H, d, J = 17 Hz, -CO-CH=), 7.80 (1H, d, J = 17 Hz, =CH-Ar), 7.45–8.25 (6H, Ar-H).
(E)-1-(3,4-dichlorophenyl)-3-(4-trifluoromethylphenyl)prop-2-en-1-one (9
): Yield 75%; m.p. 169 ◦C; FTIR
(KBr, cm−1): 1652 (C=O), 1586 (C=C quadrant of Ar), 1521 (CH=CH), 922 (C-F); 1H-NMR (400 MHz,
CDCl3, ppm): 7.35 (1H, d, J = 17 Hz, -CO-CH=), 7.69 (1H, d, J = 17 Hz, =CH-Ar), 7.22–8.09 (7H, Ar-H).
(E)-1-(3,4-dichlorophenyl)-3-(pyridin-2-yl)prop-2-en-1-one (11): Yield 43%; m.p. 156 ◦C; FTIR (KBr, cm−1):
1656 (C=O), 1600 (C=C of Ar), 1598 (C=N), 1512 (CH=CH), 1377 (C-N), 822 (C-Cl); 1H-NMR (400 MHz,
CDCl3, ppm): 7.18 (1H, d, J = 17 Hz, -CO-CH=), 7.61 (1H, d, J = 17 Hz, =CH-Ar), 6.37–8.15 (7H, Ar-H).
(E)-1-(3,4-dichlorophenyl)-3-(pyridin-3-yl)prop-2-en-1-one (12): Yield 53%; m.p. 191 ◦C; FTIR (KBr, cm−1):
1655 (C=O), 1602 (C=C of Ar), 1591 (C=N), 1510 (CH=CH), 1371 (C-N), 828 (C-Cl); 1H-NMR (400 MHz,
CDCl3, ppm): 7.19 (1H, d, J = 17 Hz, -CO-CH=), 7.71 (1H, d, J = 17 Hz, =CH-Ar), 7.11–8.25 (7H, Ar-H).
(E)-1-(3,4-dichlorophenyl)-3-(furan-2-yl)prop-2-en-1-one (14): Yield 55%; m.p. 172 ◦C; FTIR (KBr, cm−1):
1649 (C=O), 1581 (C=C of Ar), 1515 (CH=CH), 836 (C-Cl); 1H-NMR (400 MHz, CDCl3, ppm): 7.20 (1H,
d, J = 17 Hz, -CO-CH=), 7.72 (1H, d, J = 17 Hz, =CH-Ar), 7.19–7.91 (6H, Ar-H).
◦
(E)-1-(3,4-dichlorophenyl)-3-(1H-pyrrol-2-yl)prop-2-en-1-one (15): Yield 46%; m.p. 238 C; FTIR (KBr,
cm−1): 1656 (C=O), 1601 (C=C of Ar), 1581 (C=N), 1512 (CH=CH), 1375 (C-N), 3233 (N-H), 821 (C-Cl);

Molecules 2020, 25, 3188
11 of 16
1H-NMR (400 MHz, CDCl3, ppm): 5.12 (1H, s, -NH), 7.08 (1H, d, J = 17 Hz, -CO-CH=), 7.68 (1H, d,
J = 17 Hz, =CH-Ar), 6.45–7.95 (6H, Ar-H).
(E)-1-(3,4-dichlorophenyl)-3-(thiophen-2-yl)prop-2-en-1-one (16): Yield 58%; m.p. 194 ◦C; FTIR (KBr, cm−1):
1661 (C=O), 1611 (C=C of Ar), 1519 (CH=CH), 628 (C-S), 823 (C-Cl); 1H-NMR (400 MHz, CDCl3, ppm):
7.14 (1H, d, J = 17 Hz, -CO-CH=), 7.72 (1H, d, J = 17 Hz, =CH-Ar), 6.69–8.14 (6H, Ar-H).
3.2.2. General Procedure for the Synthesis of Dihydropyrazoles (17–31)
Chalcones of 3,4-dichloroacetophenone (0.005 mol) and phenyl hydrazine hydrochloride
(0.005 mol) were dissolved in glacial acetic acid (10 mL). Later, the mixture was refluxed for 6–8 h,
the solvent was evaporated completely, and dried solid was obtained. The solid thus obtained was
purified by silica gel column chromatography using mixtures of ethyl acetate in n-hexane (5–75%) and
further recrystallized from chloroform.
3-(3,4-dichlorophenyl)-1-phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazole (17): Yield 55%; m.p. 168 ◦C; FTIR (KBr,
cm−1): 1592 (C=N), 1120 (C-N), 1586 (C=C quadrant of Ar), 830 (C-Cl); 1H-NMR (400 MHz, CDCl3,
ppm): 3.28 (1H, d, HA), 3.72 (1H, d, HB), 5.45 (1H, d, Hx), 2.34 (3H, s, Ar-CH3), 6.75–7.91 (12H, Ar-H);
13C-NMR (100 MHz, CDCl3, ppm): 22.46 (-CH3), 66.54 (C-4), 45.50 (C-5), 152.50 (C-3), 133.95 (C-20 and
C-200), 143.51 (C-30 and C-300), 134.88 (C-40 and C-400), 112.12–145.96 (Ar-C’s); MS (m/z, %): 381.30 (M+),
383.30 (M + 2).
3-(3,4-dichlorophenyl)-1-phenyl-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole (18): Yield 70%; m.p. 195 ◦C;
FTIR (KBr, cm−1): 1644 (C=N), 1099 (C-N), 1582 (C=C quadrant of Ar), 835 (C-Cl), 922 (C-F); 1H-NMR
(400 MHz, CDCl3, ppm): 3.29 (1H, d, HA), 3.75 (1H, d, HB), 5.33 (1H, d, HX), 6.65–7.65 (12H, Ar-H).
3-(3,4-dichlorophenyl)-1-phenyl-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazole (19): Yield 61%; m.p. 149 ◦C;
FTIR (KBr, cm−1): 1599 (C=N), 1105 (C-N), 1578 (C=C quadrant of Ar), 825 (C-Cl), 925 (C-F); 1H-NMR
(400 MHz, CDCl3, ppm): 3.26 (1H, d, HA), 3.72 (1H, d, HB), 5.46 (1H, d, HX), 6.66–7.55 (12H, Ar-H).
3-(3,4-dichlorophenyl)-1-phenyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole (20): Yield 75%; m.p. 261 ◦C;
FTIR (KBr, cm−1): 1549 (C=N), 1091 (C-N), 1582 (C=C quadrant of Ar), 838 (C-Cl), 846 (C-Cl); 1H-NMR
(400 MHz, CDCl3, ppm): 3.28 (1H, d, HA), 3.77 (1H, d, HB), 5.49 (1H, d, HX), 6.56–7.39 (12H, Ar-H).
3-(3,4-dichlorophenyl)-1-phenyl-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazole (21): Yield 72%; m.p. 133 ◦C;
FTIR (KBr, cm−1): 1552 (C=O), 1591 (C=C quadrant of Ar), 832 (C-Cl), 838 (C-Cl); 1H-NMR (400 MHz,
CDCl3, ppm): 3.24 (1H, d, HA), 3.71 (1H, d, HB), 5.42 (1H, d, HX), 6.69–7.42 (12H, Ar-H).
3-(3,4-dichlorophenyl)-1-phenyl-5-(2,4-difluorophenyl)-4,5-dihydro-1H-pyrazole (22): Yield 81%; m.p. 291 ◦C;
FTIR (KBr, cm−1): 1526 (C=N), 1086 (C-N), 1588 (C=C quadrant of Ar), 831 (C-Cl), 921 (C-F); 1H-NMR
(400 MHz, CDCl3, ppm): 3.25 (1H, d, HA), 3.73 (1H, d, HB), 5.49 (1H, d, HX), 6.87–7.69 (11H, Ar-H).
3-(3,4-dichlorophenyl)-1-phenyl-5-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole (23): Yield 85%; m.p. 302 ◦C;
FTIR (KBr, cm−1): 1544 (C=N), 1081 (C-N), 1578 (C=C quadrant of Ar), 821 (C-Cl), 829 (C-Cl); 1H-NMR
(400 MHz, CDCl3, ppm): 3.26 (1H, d, HA), 3.81 (1H, d, HB), 5.52 (1H, d, HX), 6.82–7.77 (11H, Ar-H).
3-(3,4-dichlorophenyl)-1-phenyl-5-(4-trifluoromethylphenyl)-4,5-dihydro-1H-pyrazole (24): Yield 66%; m.p.
125 ◦C; FTIR (KBr, cm−1): 1641 (C=N), 1152 (C-N), 1568 (C=C quadrant of Ar), 818 (C-Cl), 926 (C-F);
1H-NMR (400 MHz, CDCl3, ppm): 3.28 (1H, d, HA), 3.76 (1H, d, HB), 5.50 (1H, d, HX), 6.61–7.81
(12H, Ar-H).
3-(3,4-dichlorophenyl)-1-phenyl-5-(benzo[d][1,3]dioxol-5-yl)-4,5-dihydro-1H-pyrazole (25): Yield 49%; m.p.
212 ◦C; FTIR (KBr, cm−1): 1595 (C=N), 1097 (C-N), 1576 (C=C quadrant of Ar), 1236 (O-CH2-O), 845
(C-Cl); 1H-NMR (400 MHz, CDCl3, ppm): 6.25 (2H,s,-O-CH2O-), 3.18 (1H, d, HA), 3.82 (1H, d, HB),
5.28 (1H, d, HX), 6.74–7.49 (11H, Ar-H).

Molecules 2020, 25, 3188
12 of 16
3-(3,4-dichlorophenyl)-1-phenyl-5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazole (26): Yield 55%; m.p. 191 ◦C; FTIR
(KBr, cm−1): 1645 (C=N), 1082 (C-N), 1591 (C=N), 1559 (C=C quadrant of Ar), 1325 (C-N); 1H-NMR
(400 MHz, CDCl3, ppm): 3.17 (1H, d, HA), 3.84 (1H, d, HB), 5.29 (1H, d, HX), 6.39–7.89 (12H, Ar-H).
3-(3,4-dichlorophenyl)-1-phenyl-5-(pyridin-3-yl)-4,5-dihydro-1H-pyrazole (27): Yield 53%; m.p. 184 ◦C; FTIR
(KBr, cm−1): 1634 (C=N) 1099 (C-N), 1591 (C=N), 1568 (C=C quadrant of Ar), 1344 (C-N); 1H-NMR
(400 MHz, CDCl3, ppm): 3.04 (1H, d, HA), 3.90 (1H, d, HB), 5.59 (1H, d, HX), 6.69–7.59 (12H, Ar-H).
3-(3,4-dichlorophenyl)-1-phenyl-5-(pyridin-4-yl)-4,5-dihydro-1H-pyrazole (28): Yield 61%; m.p. 214 ◦C; FTIR
(KBr, cm−1): 1641 (C=N), 1086 (C-N), 1577 (C=N), 1559 (C=C quadrant of Ar), 1335 (C-N); 1H-NMR
(400 MHz, CDCl3, ppm): 3.17 (1H, d, HA), 3.87 (1H, d, HB), 5.27 (1H, d, HX), 6.79–7.44 (12H, Ar-H).
3-(3,4-dichlorophenyl)-1-phenyl-5-(furan-2-yl)-4,5-dihydro-1H-pyrazole (29): Yield 58%; m.p. 200 ◦C; FTIR
1
(KBr, cm−1): 1612 (C=N), 1091 (C-N), 1555 (C=C quadrant of Ar), 835 (C-Cl); H-NMR (400 MHz,
CDCl3, ppm): 3.14 (1H, d, HA), 3.85 (1H, d, HB), 5.34 (1H, d, HX), 6.44–7.79 (11H, Ar-H).
3-(3,4-dichlorophenyl)-1-phenyl-5-(1H-pyrrol-2-yl)-4,5-dihydro-1H-pyrazole (30): Yield 48%; m.p. 171 ◦C;
FTIR (KBr, cm−1): 1643 (C=N), 1087 (C-N), 1564 (C=C quadrant of Ar), 1584 (C=N), 3240 (N-H), 1371
(C-N), 828 (C-Cl); 1H-NMR (400 MHz, CDCl3, ppm): 3.14 (1H, d, HA), 3.84 (1H, d, HB), 5.56 (1H, s,
-NH), 5.24 (1H, d, HX), 6.49–7.59 (11H, Ar-H).
3-(3,4-dichlorophenyl)-1-phenyl-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole (31): Yield 41%; m.p. 212 ◦C;
FTIR (KBr, cm−1): 1646 (C=N), 1145 (C-N), 1549 (C=C quadrant of Ar), 633 (C-S), 826 (C-Cl); 1H-NMR
(400 MHz, CDCl3, ppm): 3.49 (1H, d, HA), 3.77 (1H, d, HB), 5.19 (1H, d, HX), 6.44–7.59 (11H, Ar-H).
3.3. Biological Activity Studies
3.3.1. Antifungal Activity
The antifungal activity of the novel chalcones (
measured against selected fungal strains such as Aspergillus niger (ATCC-6275, An) and Candida tropicalis
(ATCC-1369, Ct) using a standard protocol published in the literature [26 27]. The serial tube dilution
2 to 16) and dihydropyrazoles (17 to 31) was
,
method employed during the anti-fungal assay determined the minimum inhibitory concentration
(MIC) values of compounds. Fluconazole was used as a standard (positive control) drug to compare
the activity. Initially, 2.048 mg of a test compound or fluconazole was dissolved in 2 mL of methanol to
obtain a concentration of 1.024 mg/mL as stock solution. The test fungal organism was grown at 37 ◦C
in Potato Dextrose Agar followed by dilution with sterile nutrient broth medium to obtain a fungal
suspension containing about 107 cells/mL. This suspension was used as the inoculum. This antifungal
assay utilized 11 test tubes, 9 of which were marked as 1, 2, 3, 4, 5, 6, 7, 8, and 9 whereas the remaining
two were assigned the names TM (medium), and TMI (medium + inoculum). An amount of 1 mL
of nutrient broth medium was transferred in to each of these 11 test tubes and then cotton plugged
followed by sterilization in an autoclave at a temperature of 121 ◦C for 30 min under the pressure of
15 psi.
Once these sterile test tubes were cooled down, 1 mL of the stock solution of a test compound
was added to the first test tube and mixed well followed by transferring 1 mL of this content to the
second test tube. The process of serial dilution was continued up to the ninth test tube. Then, 10
diluted inoculum containing about 107 cells/mL of a fungal strain was added to each of the nine test
tubes and mixed well. Another 10 L of the inoculum was also added to the test tube marked TMI to
µL of
µ
observe the growth of the organism in the medium used. The control test tube TM containing only the
medium was used to confirm the sterility of the medium. All the test tubes were incubated at 37 ◦C
for 18 h. A similar experiment with medium, methanol, and inoculum without the compound was
also performed to ensure that the methanol (negative control) had no inhibitory effect in the dilutions
used. The test tube number in which the first sign of growth of the organism was observed was noted.
The MIC was calculated as the concentration used in the test tube number just prior to the test tube

Molecules 2020, 25, 3188
13 of 16
number where the first sign of growth was observed. This procedure was followed in triplicate to
determine the MIC values for all the compounds and the results were considered the average of three
values. As the standard drug fluconazole is structurally different from the target compounds, the MIC
values obtained in µg/mL were converted to molar concentration in the form of µM.
3.3.2. Antitubercular Activity
The antitubercular activity of all the test compounds was tested for against the Mycobacterium
tuberculosis H37Rv strain, employing pyrazinamide as the reference standard according to the standard
procedure described in the literature [21,22,24,25,27,48]. A frozen culture in Middlebrook 7H9 broth
with the addition of 0.2% glycerol and 10% albumin-dextrose-catalase was thawed and diluted in broth
to 105 CFU mL−1 (colony forming unit/mL) dilutions. Each test compound was dissolved separately in
DMSO followed by dilution with broth to attain a concentration which was two times the required
concentration. During this experiment, the final concentration of DMSO in the assay medium was 1.3%.
Each U-tube was then inoculated with 0.05 mL of standardized culture and later incubated at 37 ◦C for
21 days. The growth in the U-tubes was compared with visibility in opposition to a positive control
(with pyrazinamide) and negative control (without drug and inoculum). A broth dilution assay was
utilized to determine the minimum inhibitory concentration (MIC) of each compound. MIC is defined
as the lowest concentration of drug or a compound that inhibits
start of the assay. The MIC values obtained in g/mL were converted to molar concentration in the form
of M as the standard drug pyrazinamide and the target compounds ( 31) were structurally diverse.
≤
99% of the bacteria present at the
µ
µ
2–
3.3.3. Antiproliferative and Cytotoxic Activity
The in vitro antiproliferative activity of chalcones (2 to 16) and dihydropyrazoles (17 to 31) was
evaluated by Mosmann’s MTT assay, as described previously [28] on prostate cancer cell lines (DU-145).
The antiproliferative activity of the compounds was determined their IC50 values. Methotrexate (Mtx;
positive control) was used as a reference standard for comparing the antiproliferative activity of the
target compounds. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay
was based on the reduction of the soluble MTT (0.5 mg mL−1, 100
µL) into a blue-purple formazan
product, mainly by the activity of mitochondrial reductase enzymes inside the living cells. The prostate
cancer cell lines, DU-145 cells, were cultured in Dulbecco’s Modified Eagle Medium (DMEM) media at
37 ◦C and humidified at 5% CO2. Stock solutions of the test compounds (17
–
46) were prepared in 0.1%
DMSO followed by dilution with sterile water to obtain the desired final concentrations. Briefly, the
cells were placed on 96-well plates at 100 L total volume with the density of 1
104 cells per well and
µ
×
were allowed to adhere for 24 h. Then the medium was replaced with fresh media containing different
dilutions of the test compounds and incubated for additional 48 h at 37 ◦C in DMEM with 10% fetal
bovine serum (FBS) medium. Subsequently, the medium was replaced with 90
without FBS. The above wells were treated with 10 L of MTT reagent (5 mg/mL of stock solution
in DMEM without FBS) and incubated at 37 ◦C for 3–4 h. The formed blue formazan crystals were
dissolved in 200 L of DMSO. The optical density was determined at 570 nm using a micro plate reader.
µL of fresh DMEM
µ
µ
The assay was performed in triplicate for three independent experiments. The same experimentation
was also done to confirm that the DMSO (negative control) had no effect in the study. The results had
good reproducibility between replicate wells with standard errors below 10%. The antiproliferative
activity results measured as IC50 values in µg/mL were converted and expressed in µM. Additionally,
the cytotoxic activity of the compounds was also measured employing the same protocol discussed
above to assess their toxicity on normal human cell lines (L02).
4. Conclusions
In the present study, we reported the antifungal, antitubercular, and antiproliferative activity
and structure–activity relationship of 30 dichlorophenyl ring-containing compounds including
15 chalcones and 15 dihydropyrazoles. Biological screening data indicated that chalcones exhibited

Molecules 2020, 25, 3188
14 of 16
better antiproliferative activity over dihydropyrazoles whereas the dihydropyrazole derivatives showed
superior antifungal and antitubercular activities. It was observed that the electronic property (electron
withdrawing) of the substituents on the phenyl ring was instrumental in the potency of the compounds.
The phenyl ring was substituted with various bioisosteres. For instance, the dihydropyrazole
with a bioisostere 2-thienyl heterocycle (31) showed potent antifungal activity on chalcone 16
Dihydropyrazoles 22 and 24 bearing 2,4-dichlorophenyl were the potent antitubercular compounds on
chalcones and and the reference standard. Chalcone 16 showed better antiproliferative activity
.
7
9
on dihydropyrazole 31 but less than the standard. Further studies are in progress to separate the
enantiomers of the dihydropyrazoles as well as to assess the mode of action of the potential compounds
that emerged from our study by biological and computational means.
Supplementary Materials: The supplementary materials are available online, FT-IR, 1H-NMR, 13C-NMR, and
MS Spectral Data and Rf values.
Author Contributions: Conceptualization, A.B.S., R.R.B., M.M.R., S.N., and S.S.; methodology, A.B.S., R.R.B.,
M.M.R., S.N., Z.E., and S.S.; software, A.B.S., S.N., Z.E., N.R.T., and S.S.; validation, A.B.S., N.R.T., and S.S.; formal
analysis, A.B.S., R.R.B., M.R., and S.N.; investigation, A.B.S., N.R.T., and S.S.; resources, A.B.S., N.R.T., S.N., and
S.S.; data curation, A.B.S., N.R.T., S.N., and S.S.; writing—original draft preparation, A.B.S., R.R.B., M.M.R., S.N.,
Z.E., N.R.T., and S.S.; writing—review and editing, A.B.S., R.R.B., M.M.R., S.N., Z.E., and S.S.; visualization, A.B.S.,
M.M.R., and S.N.; supervision, A.B.S.; project administration, A.B.S., S.N., and S.S.; funding acquisition, A.B.S.,
R.R.B., N.R.T., and S.S. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Acknowledgments: The authors would like to acknowledge Vignan Pharmacy College, Vadlamudi, Andhra
Pradesh, India for providing the lab facilities and chemicals for this work. R.R.B. and Z.E. would like to thank the
Dean’s Office of the College of Pharmacy and Health Sciences, Ajman University, UAE for their support in the
preparation of this manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
Yazdan, K.S.; Sagar, G.V.; Shaik, B.A. Biological and synthetic potentiality of chalcones: A review. J. Chem.
Pharm. Res. 2015, 7, 829–842.
Habib, S.I. Chemical and Biological Potential of chalcones as a source of drug: A review. Int. J. Pharm.
Pharm. Res. 2018, 22, 105–119.
Hasan, S.A.; Elias, A.N.; Farhan, M.S. Synthesis, characterization and antimicrobial evaluation of a series of
chalcone derivatives. Der Pharma. Chem. 2015, 7, 39–42.
Kumbhar, D.D.; Waghmare, B.Y.; Pathade, G.R.; Pardeshi, S.K. Synthesis and evaluation of chalcones as
antifungal agents. Der Pharma. Lett. 2014, 6, 224–229.
Jaiswal, P.; Pathak, D.P.; Bansal, H.; Agarwal, U. Chalcone and their heterocyclic analogue: A review article.
J. Chem. Pharm. Res. 2018, 10, 160–173.
Zhuang, C.; Zhang, W.; Sheng, C.; Zhang, W.; Xing, C.; Miao, Z. Chalcone: A Privileged Structure in
Medicinal Chemistry. Chem. Rev. 2017, 117, 7762–7810. [CrossRef]
Gomes, M.N.; Muratov, E.N.; Pereira, M.; Peixoto, J.C.; Rosseto, L.P.; Cravo, P.V.L.; Andrade, C.H.; Neves, B.J.
Chalcone Derivatives: Promising Starting Points for Drug Design. Molecules 2017, 22, 1210. [CrossRef]
Gibson, M.Z.; Nguyen, M.A.; Zingales, S.K. Design, synthesis and evaluation of (2-(Pyridinyl)methylene)-1-
tetralone chalcones for Anticancer and Antimicrobial Activity. Med. Chem. 2018, 14, 333–343. [CrossRef]
Insuasty, B.; Montoya, A.; Becerra, D.; Quiroga, J.; Abonia, R.; Robledo, S.; Velez, I.D.; Upegui, Y.; Nogueras, M.;
Cobo, J. Synthesis of novel analogs of 2-pyrazoline obtained from [(7-chloroquinolin-4-yl)amino]chalcones
and hydrazine as potential antitumor and antimalarial agents. Eur. J. Med. Chem. 2013, 67, 252–262.
[CrossRef]
10. Wang, J.; Huang, L.; Cheng, C.; Li, G.; Xie, J.; Shen, M.; Chen, Q.; Li, W.; He, W.; Qiu, P.; et al. Design,
synthesis and biological evaluation of chalcone analogues with novel dual antioxidant mechanisms as
potential anti-ischemic stroke agents. Acta Pharm. Sin. B 2019, 9, 335–350. [CrossRef]

Molecules 2020, 25, 3188
15 of 16
11. Martinez, Y.A.V.; Osorio, M.E.; San Martin, D.A.; Carvajal, M.A.; Vergera, A.P.; Sanchez, E.; Raimondi, M.;
Zacchino, S.A.; Mascayano, C.; Torrent, C.; et al. Antimicrobial, Anti-Inflammatory and Antioxidant
Activities of Polyoxygenated Chalcones. J. Braz. Chem. Soc. 2019, 30, 286–304.
12. Karthikeyan, C.; Moorthy, N.S.H.N.; Ramasamy, S.; Vanam, U.; Manivannan, E.; Karunagaran, D.; Trivedi, P.
Advances in chalcones with anticancer activities. Recent Pat. Anti-Cancer Drug Discov. 2015, 10, 97–115.
[CrossRef] [PubMed]
13. Szliszka, E.; Czuba, Z.; Mazur, B.; Paradysz, A.; Krol, W. Chalcones and Dihydrochalcones Augment
TRAIL-Mediated Apoptosis in Prostate Cancer Cells. Molecules 2010, 15, 5336–5353. [CrossRef] [PubMed]
14. Lavanya, G.; Mallikarjunareddy, L.; Padmavathi, V.; Padmaja, A. Synthesis and antimicrobial activity of
(1,4-phenylene)bis(arylsulfonylpyrazoles and isoxazoles). Eur. J. Med. Chem. 2014, 73, 187–194. [CrossRef]
15. Ardiansah, B. Chalcones bearing N, O and S-heterocycle: Recent notes on their biological significance. J. Appl.
Pharm. Sci. 2019, 9, 117–129.
16. Abdelhamid, A.O.; EI Sayed, I.E.; Zaki, Y.H.; Hussein, A.M.; Mangoud, M.M.; Hosny, M.A. Utility
of 5-(furan-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide in the synthesis of heterocyclic
compounds with antimicrobial activity. BMC Chem. 2019, 13, 48. [CrossRef]
17. Hassan, S.Y. Synthesis, antibacterial and antifungal activity of some new pyrazoline and pyrazole derivatives.
Molecules 2013, 18, 2683–2711. [CrossRef]
18. Havrylyuk, D.; Kovach, N.; Zimenkovsky, B.; Vasylenko, O.; Lesyk, R. Synthesis and anticancer activity of
isatin-based pyrazolines and thiazolidines conjugates. Arch. Der Pharm. 2011, 344, 514–522. [CrossRef]
19. Gawad, N.M.; Georgey, H.H.; Ibrahim, N.A.; Amin, N.H.; Abdelsalam, R.M. Synthesis of novel pyrazole
and dihydropyrazoles derivatives as potential anti-inflammatory and analgesic agents. Arch. Pharmacal Res.
2016, 52, 14490–14493. [CrossRef]
20. Alex, J.M.; Kumar, R. 4,5-Dihydro-1H-pyrazole: An indispensable scaffold. J. Enzym. Inhib. Med. Chem. 2014
,
29, 427–442. [CrossRef]
21. Kishor, P.; Ramana, V.; Shaikh, A.B. Antitubercular Evaluation of Isoxazolyl Chalcones. Res. J. Pharm. Biol.
Chem. Sci. 2017, 8, 730–735.
22. Shaikh, A.B.; Lohitha, K.; Vani, S.; Basu, P.S.; Shaik, A.; Supraja, K.; Harish, S.H. Synthesis and screening
of novel lipophilic diarylpropeones as prospective antitubercular, antibacterial and antifungal agents.
Biointerface Res. Appl. Chem. 2019, 9, 3912–3918.
23. Shaikh, A.B.; Prasad, Y.R.; Shaik, S. Design, Facile Synthesis, Characterization and Computational Evaluation
of Novel Isobutylchalcones as Cytotoxic Agents: Part-A. FABAD J. Pharm. Sci. 2015, 40, 7–22.
24. Kancharlapalli, V.R.; Shaikh, A.B.; Palleapati, K. Antitubercular evaluation of isoxazole appended
1-carboxamido-4,5-dihydro-1H-pyrazoles. J. Res. Pharm. 2019, 23, 156–163.
25. Lokesh, B.V.S.; Prasad, Y.R.; Shaik, A.B. Synthesis, Biological evaluation and molecular docking studies of
new pyrazolines as an antitubercular and cytotoxic agents. Infect. Disord. -Drug Targets Former. Curr. Drug
Targets-Infect. Disord. 2019, 19, 310–321. [CrossRef]
26. Shaik, A.B.; Yejella, R.P.; Shaik, S. Synthesis, Antimicrobial, and Computational Evaluation of Novel
Isobutylchalcones as Antimicrobial Agents. Int. J. Med. Chem. 2017, 2017, 1–14. [CrossRef]
27. Lokesh, B.V.S.; Prasad, Y.R.; Shaik, A.B. Novel pyrimidine derivatives from 2,5-dichloro-3-acetylthienyl
chalcones as antifungal, antitubercular and cytotoxic agents: Design, synthesis, biological activity and
docking study. Asian J. Chem. 2019, 19, 310–321.
28. Shaikh, A.B.; Bhandare, R.R.; Palleapati, K.; Nissankararao, S.; Kancharlapalli, V.; Shaik, S. Antimicrobial,
antioxidant, and anticancer activities of some novel isoxazole ring containing chalcone and dihydropyrazole
derivatives. Molecules 2020, 25, 1047. [CrossRef]
29. Ocampo, J.A.; Carrillo, R.; Kae, H.; Ashburn, B.O. Synthesis and antimicrobial evaluation of a series of
chlorinated chalcone derivatives. Int. J. Pharm. 2018, 13, 113–119.
30. Montoya, A.; Quiroga, J.; Abonia, R.; Derita, M.; Sortino, M.; Ornelas, A.; Zacchino, S.; Insuasty, B.
Hybrid molecules containing a 7-chloro-4-aminoquinoline nucleus and a substituted 2-pyrazoline with
antiproliferative and antifungal activity. Molecules 2016, 21, 969. [CrossRef]
31. Bano, S.; Alam, M.S.; Javed, K.; Dudeja, M.; Das, A.K.; Dhulap, A. Synthesis, biological evaluation and
molecular docking of some substituted pyrazolines and isoxazolines as potential antimicrobial agents. Eur. J.
Med. Chem. 2015, 95, 96–103. [CrossRef]

Molecules 2020, 25, 3188
16 of 16
32. Karad, S.C.; Purohit, V.B.; Thakor, P.; Thakkar, V.R.; Raval, D.K. Novel morpholinoquinoline nucleus clubbed
with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities. Eur. J. Med. Chem.
2016, 112, 270–279. [CrossRef] [PubMed]
33. Ahsan, M.J.; Saini, V. Design and synthesis of 3-(4-aminophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-
pyrazole-1-carboxamide/carbothioamide analogues as antitubercular agents. Beni-Suef Univ. J. Basic Appl. Sci.
2015, 4, 41–46. [CrossRef]
34. Ashburn, B.O. Computational Analysis of a Series of Chlorinated Chalcone Derivatives. Comput. Chem. 2019
,
7, 106–120. [CrossRef]
35. Fang, W.Y.; Ravindar, L.; Rakesh, K.P.; Manukumar, H.M.; Shantharam, C.S.; Alharbi, N.S.; Qin, H.L. Synthetic
approaches and pharmaceutical applications of chloro-containing molecules for drug discovery: A critical
review. Eur. J. Med. Chem. 2019, 173, 117–153. [CrossRef]
36. Smith, B.R.; Eastman, C.M.; Njardarson, J.T. Beyond C, H, O, and N! Analysis of the Elemental Composition
of U.S. FDA Approved Drug Architectures. J. Med. Chem. 2014, 57, 9764–9773. [CrossRef]
37. Mueller, G.; Nkusi, G.; Schoeler, H.F. Natural Organohalogens in Sediments. J. Prakt. Chem./Chem. -Ztg. 1996
,
338, 23–29. [CrossRef]
38. Klaus, N. Influence of chlorine substituents on biological activity of chemicals: A review. Pest Manag. Sci.
2000, 56, 3–21.
39. Wilcken, R.; Zimmermann, M.O.; Lange, A.; Joerger, A.C.; Boeckler, F.M. Principles and Applications of
Halogen Bonding in Medicinal Chemistry and Chemical Biology. J. Med. Chem. 2013, 56, 1363–1388.
[CrossRef]
40. Mendez, L.; Henriquez, G.; Sirimulla, S.; Narayan, M. Looking Back, Looking Forward at Halogen Bonding
in Drug Discovery. Molecules 2017, 22, 1397. [CrossRef]
41. Edis, Z.; Haj Bloukh, S.; Abu Sara, H.; Bhakhoa, H.; Rhyman, L.; Ramasami, P. “Smart” triiodide compounds:
Does halogen bonding influence antimicrobial activities? Pathogens 2019, 8, 182. [CrossRef] [PubMed]
42. Bloukh, S.H.; Edis, Z. Halogen bonding in Crystal structure of bis(1,4,7,10-tetraoxacyclododecane-
κ4O,O0,O00,O000)cesium triiodide, C16H32CsI3O8. Z. Krist. -New Cryst. Struct. 2020, in press. [CrossRef]
43. Bloukh, S.H.; Edis, Z. Structure and Antimicrobial properties of bis(1,4,7,10-tetraoxacyclododecane-
κ4O,O0,O00,O000)cesium pentaiodide, C16H32CsI5O8. Z. Krist. -New Cryst. Struct. 2020, in press. [CrossRef]
44. Thirunarayanan, G.; Surya, S.; Srinivasan, S.; Vanangamudi, G.; Sathiyendiran, V. Synthesis and insect
antifeedant activities of some substituted styryl 3,4-dichlorophenyl ketones. Spectrochim. Acta Part A Mol.
Biomol. Spectrosc. 2010, 75, 152–156. [CrossRef] [PubMed]
45. Buu-Hoi, N.P.; Xuong, N.D.; Rips, R. New Fluorine-containing Aromatics as Potential Carcinostats.
J. Org. Chem. 1957, 22, 193–197. [CrossRef]
46. Hicks, L.D.; Fry, A.J.; Kurzweil, V.C. Ab initio computation of electron affinities of substituted
benzalacetophenones (chalcones): A new approach to substituent effects in organic electrochemistry.
Electrochim. Acta 2004, 50, 1039–1047. [CrossRef]
47. Aeppli, L.; Bernauer, K.; Schneider, F.; Strub, K.; Oberhänsli, W.E.; Pfoertner, K.-H. Synthesen und
pharmakologische Eigenschaften von 2,2-Dialkyl-5-aryl-3-pyridylpyrrolidinen. Helv. Chim. Acta 1980
63, 630–644. [CrossRef]
,
48. Anandham, R.; Jadav, S.S.; Ala, V.B.; Ahsan, M.J.; Bollikolla, H.B. Synthesis of new C-dimethylated chalcones
as potent antitubercular agents. Med. Chem. Res. 2018, 27, 1690–1704. [CrossRef]
Sample Availability: Samples of the compounds 2–31 are available from the authors.
©
2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).